Filing Details

Accession Number:
0001209191-22-057985
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-11-18 18:42:04
Reporting Period:
2022-11-16
Accepted Time:
2022-11-18 18:42:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1743881 Bridgebio Pharma Inc. BBIO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1742485 Neil Kumar C/O Bridgebio Pharma, Inc.
421 Kipling Street
Palo Alto CA 94301
Ceo And President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-11-16 68,706 $0.00 4,881,903 No 4 M Direct
Common Stock Disposition 2022-11-16 34,066 $9.64 4,847,837 No 4 F Direct
Common Stock Disposition 2022-11-17 34,640 $9.40 4,813,197 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2022-11-16 5,130 $0.00 5,130 $0.00
Common Stock Restricted Stock Units Disposition 2022-11-16 2,394 $0.00 2,394 $0.00
Common Stock Restricted Stock Units Disposition 2022-11-16 61,182 $0.00 61,182 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,776 No 4 M Direct
21,548 No 4 M Direct
305,910 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,612,722 Indirect See Footnote
Common Stock 1,195,686 Indirect See Footnote
Footnotes
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  2. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 68,706 shares of Common Stock underlying the Reporting Person's RSUs.
  3. Represents the weighted average sale price of the shares sold from $9.16 to $9.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.
  4. The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
  5. The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
  6. The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
  7. The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
  8. The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.